title: A retrospective study of the novel combination of paclitaxel and S1 for pretreated advanced non-small cell lung cancer.
abstract: BACKGROUND
  Recently, multiple-line chemotherapy has become popular for non-small cell lung cancer (NSCLC). The survival time of patients is influenced by patient characteristics and subsequent treatments.
  
  
  METHODS
  The usefulness of paclitaxel plus S1 (PTX+S1) was evaluated in 46 pretreated NSCLC patients. Time from the start of individual regimens till the start of the next one (TNR) was calculated for regimens administered to the study population including PTX+S1 and analyzed by the shared frailty Cox model.
  
  
  RESULTS
  The response rate and the median progression-free survival time of PTX+S1 were 32.6% and 253 days, respectively. Substantial difference in TNR was observed in epidermal growth factor receptor mutation status and in line and type of regimens, but not in stage, age, sex, performance status and histology, by univariate analysis. Multivariate analysis revealed that PTX+S1 was only one factor to prolong TNR.
  
  
  CONCLUSIONS
  Because of long progression-free survival and long TNR, further evaluation of PTX+S1 is necessary.
authors: Department of Medical Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka 537-8511, Japan.
authors: Nana
authors: N
authors: Aono
authors: Yuri
authors: Y
authors: Ito
authors: Kazumi
authors: K
authors: Nishino
authors: Junji
authors: J
authors: Uchida
authors: Toru
authors: T
authors: Kumagai
authors: Yuki
authors: Y
authors: Akazawa
authors: Takako
authors: T
authors: Okuyama
authors: Tetsuhiro
authors: T
authors: Yoshinami
authors: Fumio
authors: F
authors: Imamura
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004338:Drug Combinations; D066246:ErbB Receptors / Q000235:genetics*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009154:Mutation; D010094:Oxonic Acid / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D066246:ErbB Receptors; D017239:Paclitaxel